Medicare Part D Smoothing Program: Impact on Access and Adherence

Key Takeaways

• The Medicare Part D smoothing program will distribute out-of-pocket costs for BTK inhibitors, potentially enhancing CLL patient adherence.
• Improved access to BTK inhibitors is anticipated due to reduced financial barriers for CLL patients under the new program.
• Pharmacists are essential in assisting providers and patients to navigate the Medicare Part D changes, ensuring effective treatment management.